Nanoparticles in Cancer Immunotherapy
Deadline for manuscript submissions: closed (30 November 2020) | Viewed by 74731
For some time now, nanomedicine has entered the mainstream of biomedical research, with immunotherapy as one of its major focus areas. Since the immune system is evolutionarily trained to respond to nano-sized objects (e.g., bacteria, viruses), these structures are well recognized by cells of the innate and adaptive immune system. Effective immunomodulation almost always requires the concurrent and coordinated delivery of several distinct signals to individual immune cells: in addition to the respective antigen to be immunized or tolerized against, costimulatory or tolerizing signals as well as signals that selectively address certain immune cell types or alter the nature of an immune response all need to be co-delivered. For this, nanoparticles are ideally suited and are thus being explored as molecular vaccines or immunomodulatory agents in many laboratories all over the world.
To modulate cancer-specific immune responses, immunotherapeutics primarily address specific immune cells within the blood or lymphatic organs, or directly within the tumor microenvironment, with the aim to either stimulate cancer-specific immune-effector cells or to inactivate tumor-promoting immunoregulatory cells. The development of vaccines that aim to activate cancer-specific T and/or B cells is one major experimental approach, but tools to address innate immune cells or to deliver immunotherapeutics directly to tumor may revolutionize cancer therapy.
This Special Issue of Cells will comprise a selection of original research papers and reviews focusing on novel approaches for nanomedicine-based cancer immunotherapy. Manuscripts on novel nanomaterials that selectively target certain immune cell populations or are able to carry peptide-, DNA- or RNA-encoded antigens, immune adjuvants, cytokines, and immunomodulators are within the focus of this Special Issue, with a preference for translational studies or studies using experimental animal models. Also within the scope of the Special Issue are studies that address determinants of cell type- or organ-selective uptake of nanoparticles, such as the serum protein corona or receptor-mediated nanoparticle uptake mechanisms. Targeted delivery of immunotherapeutics to solid tumors or nanoparticle-based imaging of cancer-specific immune responses are also welcome topics.
Prof. Dr. Stephan Grabbe
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer immunotherapy
- cancer vaccines
- tumor microenvironment